Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > GLP-1 Receptor Agonist Market

GLP-1 Receptor Agonist Market Share

Report ID: GMI5864
Published Date: May 2023
Report Format: PDF

Download Free Sample

GLP-1 Receptor Agonist Market Share

The key players in GLP-1 receptor agonist market are

Eli Lilly and Company
Sanofi
Novo-Nordisk A/S
AstraZeneca
Pfizer.Inc
Amgen, Inc.
Innovent Biologics, Inc.
PegBio Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for GLP-1 receptor agonist was around USD 22.4 billion in 2022 and will exhibit sustainable growth at around 9.6% CAGR from 2023 to 2032.

Global GLP-1 receptor agonist industry from the type 2 diabetes mellitus segment accounted for the largest share in 2022 as they play a vital role in stimulating the release of insulin and suppressing glucagon secretion when the blood glucose levels are high.

North America held the highest revenue share GLP-1 receptor agonist market in 2022, owing to a high prevalence of chronic diseases such as diabetes and obesity, and increasing investments for R&D for developing new drugs for treating diabetes and obesity.

Eli Lilly and Company, Sanofi, Pfizer.Inc, Amgen, Inc., Novo-Nordisk A/S, AstraZeneca, Innovent Biologics, Inc., Sun Pharmaceutical Industries Ltd., PegBio Co., Ltd., and Boehringer Ingelheim International GmbH.